Reaction Biology Corp., Malvern, Penn., has been awarded a Phase I SBIR grant from the National Institutes of Health's National Center for Advancing Translational Sciences to create a database of epigenetic drug interactions. The grant will help fund an examination of the interaction of over 1,400 FDA-approved drugs and drug-like compounds with over 30 epigenetic modifying enzymes. The project will begin immediately at RBC's lab facilities, and will last for one year.
All Health Data Management articles are archived after 7 days. REGISTER NOW for unlimited access to all recently archived articles, as well as thousands of searchable stories. Registered Members also gain access to exclusive industry white paper downloads, web seminars, podcasts, e-books, and conference discounts. Qualified members may also choose to receive our free monthly magazine and any of our e-newsletters covering the latest breaking news, opinions from industry leaders, developing trends and specialized topics like EHR's, revenue cycle management, health insurance exchanges, analytics, and more!